Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema by David, Owens
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Current Medical Research & Opinion
                                              
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa35083
_____________________________________________________________
 
Paper:
Holden, S., Currie, C. & Owens, D. (2017).  Evaluation of the clinical effectiveness in routine practice of fluocinolone
acetonide 190 µg intravitreal implant in people with diabetic macular oedema. Current Medical Research & Opinion
 
 
 
 
 
 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
  1 
Evaluation of the clinical effectiveness in routine practice of 
fluocinolone acetonide 190 µg intravitreal implant in people 
with diabetic macular oedema 
Sarah E. Holden1, Craig J. Currie1,2, David R Owens3 
1. Global Pharmacoepidemiology, Pharmatelligence, Cardiff, UK  
2. Institute of Population Medicine, Cardiff University, Cardiff, UK  
3. School of Medicine, Swansea University, Swansea, UK 
 
Address for correspondence 
Professor Craig Currie 
Professor of Applied Pharmacoepidemiology 
Institute of Population Medicine 
School of Medicine 
Cardiff University 
Pharma Research Centre, Abton House 
Wedal Road 
Cardiff CF14 3QX 
United Kingdom  
Email: currie@cardiff.ac.uk 
 
Manuscript details 
Abstract 252 words 
Body  4,240 words 
Tables  5 
Figures  4 
References 23 
Supp tables 1 
Supp figures 3 
  
 2 
Abstract  
Objective 
The aim of the ILUVIEN Clinical Evidence study in the United Kingdom (ICE-UK) was 
to assess the real-world effectiveness of fluocinolone acetonide (FAc) 190 µg 
intravitreal implant for the treatment of clinically significant chronic diabetic macular 
oedema (DMO) in routine clinical practice.  
Methods 
This retrospective study collected data from patient medical records in 13 
ophthalmology centres for people with DMO prescribed FAc intravitreal implant 
between 1 April 2013 and 15 April 2016. Visual acuity (VA) and intraocular pressure 
(IOP) measurements were collected for 12 months prior to and after implant.  
Results 
208 people contributing 233 eyes treated with FAc implant were included. Mean age 
was 68.1 years and 62% were male. In the 12 months prior to FAc implant, VA 
declined. Median (interquartile range, IQR) VA was 0.66 (0.50–1.00) LogMAR units 
(equivalent to 52.0 ETDRS letters) at implant, improving to 0.60 (0.40–0.86) LogMAR 
units (55.0 letters) at 12 months post implant (p<0.001). 44%, 30% and 18% of 
people achieved an improvement in ETDRS score of ≥5, ≥10 and ≥15 letters, 
respectively, over the same period. A small but significant (p<0.001) increase in 
median IOP was observed (median 15.0, IQR 13.0–18.0 mmHg at implant to 18.0, 
15.0–21.0 mmHg at 12 months). In the 12 months following implant, additional IOP-
lowering therapy was prescribed in 15% of subjects previously not requiring such 
therapy. 
Conclusion 
Following FAc implant, an overall significant improvement in VA was observed over a 
period of 12 months, accompanied by a significant but small increase in IOP. 
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Introduction 
The fluocinolone acetonide (FAc) 190 µg intravitreal implant has been licensed in 17 
European countries for the management of chronic diabetic macular oedema (DMO) 
when other treatments have proven to be insufficiently effective. The approval of 
the FAc implant was based on data from the Fluocinolone Acetonide in Diabetic 
Macular Edema (FAME) study programme.1 This programme comprised two separate 
randomised controlled trials, FAME A and FAME B, and studied the clinical 
effectiveness of the FAc intravitreal implant in DMO.2,3 Analysis of the combined 
data demonstrated that, versus the patients randomised to sham injection, the FAc 
0.2µg/day intravitreal implant provided significant visual benefits over the three year 
period of follow-up.2,3  
However, the treatment paradigm for centre-involving clinically significant DMO has 
changed since the FAME studies were conducted. At that time, laser 
photocoagulation was considered to be the cornerstone in the management of 
DMO, supported by evidence from the Early Treatment Diabetic Retinopathy Study 
(ETDRS).4 However, several landmark trials have since demonstrated that anti-VEGF 
therapy can lead to an improvement in vision in people with DMO5–8 and therefore 
anti-VEGF therapy is now considered to be the gold-standard, first-line treatment for 
the condition. People recruited for the FAME studies were previously treated with 
retinal laser therapy with no prior history of exposure to anti-VEGF therapies.2,3 As 
the FAc intravitreal implant is currently only indicated when available therapies have 
proved to be insufficiently effective, there is a need to determine the effectiveness 
of FAc in those individuals previously exposed to anti-VEGF therapy. 
The role of real-world clinical evidence in supplementing clinical trial data has been 
acknowledged by regulatory authorities,9 with eye disorders previously investigated 
using either prospective (HELIOS)10 or retrospective designs (TWIN).11 Studies 
investigating the effectiveness of the FAc intravitreal implant using real-world data 
are limited, with most of the studies being short-term follow-up studies with small 
participant numbers and/or limited data collection.12–16 However, in a recently 
published, larger prospective study by El-Ghrably and colleagues involving DMO 
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subjects previously treated with anti-VEGF (n=57), an improvement in best-corrected 
visual acuity and central macular thickness was observed at 3 months post FAc 
implant, with a sustained effect observed for the remainder of the 12 month follow-
up period.17  
Since FAME, no randomised clinical trials have been conducted to assess the impact 
of FAc intravitreal implant on visual acuity and other clinical outcomes after 
treatment with anti-VEGF. Therefore, the aim of the ILUVIEN Clinical Evidence study 
in the United Kingdom (ICE-UK) was to assess the real-world effectiveness of FAc 
intravitreal implant in routine clinical practice. Additionally, the project was 
conducted to assess the long-term effect of FAc intravitreal implant on intraocular 
pressure (IOP) and its management in clinical practice. The real-world evidence 
generated by the clinical use of FAc intravitreal implant since 2013 represents a 
retrospective method of collecting the evidence on treatment outcomes. The study 
design enabled data to be collected for at least 12 months prior to and at least 12 
months post implant. The collection of data prior to implant is of considerable 
advantage to this study and is rarely available from randomised controlled trials.   
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Methods 
Data Source 
A retrospective cohort study was conducted. In this multi-centre, hospital-based 
study, data were taken from the medical records. Data collection was secondary, as 
the data used for this study were initially collected for purposes other than research. 
Data were collected from a representative cohort of people treated at 13 
participating hospitals in the UK and combined into a single dataset for the purpose 
of analysis. These data were pseudonymised and entered into an online data entry 
tool (Real World Treatment Evaluator), where centre and subject identifiers were 
added. Data generated from retrospective case reviews were entered by the 
consultant themselves or by other members of the healthcare professional’s team.  
Data included demographics, medical history, implant data, and data from multi-
disciplinary and medication reviews at several time points within a designated period 
(see Supplementary Figure 1). Quantitative data were generated from medical 
records, administrative records and clinical measurements and were collected only 
for those parameters that were necessary to answer the research question. 
Summaries by site were not performed other than for analysis relevant to evaluation 
of their healthcare service. No data linkage took place in the course of this project. 
At no point did Alimera Sciences, the manufacturer of ILUVIEN, have access to the 
data. 
 
Ethical approval 
The lead clinician and Caldicott Guardian at each centre gave written approval for 
extraction of anonymised data. The study protocol was approved by the head of 
research governance at the lead clinical centre. This study was conducted in 
accordance with the Declaration of Helsinki and the UK Data Protection Act. 
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Subjects 
A cohort of people prescribed FAc 190 µg intravitreal implant was constructed based 
on past exposure to FAc intravitreal implant. People with type 1 and type 2 diabetes 
treated with FAc intravitreal implant for DMO in at least one eye were included in 
the cohort if they had received an implant at a participating site as part of their 
routine care between 1 April 2013 and 15 April 2015 and had a minimum of 12 
months’ history prior to implant. Subjects were excluded from the study if they had 
been involved in other, prior interventional studies for DMO. People who had 
insufficient follow-up because they had left the clinic, had no visits or had missed 
their last appointment post-index were also excluded from the study.  
The index date was defined as the date of first recorded FAc intravitreal implant into 
the study eye. All subjects were followed from implant for one year. As the end of 
the observation period was 15 April 2016, all selected subjects had a follow-up of at 
least one year post implant. Individuals that received FAc intravitreal implant in both 
eyes were allowed to contribute both eyes to the study.  
  
Outcomes 
For these analyses, the following clinical outcomes were investigated at 3, 6 and 12 
months post index date: change in visual acuity on the LogMAR (Logarithm of the 
Minimum Angle of Resolution) scale; proportion of eyes that demonstrated an 
improvement in ETDRS score of ≥5 letters, ≥10 letters and ≥15 letters; and change in 
IOP from implant.  
Visual acuity was measured using one of: ETDRS scores, Snellen fractions or LogMAR 
scores. Snellen fractions were converted to approximate ETDRS scores for the 
purpose of analysis using the following formula derived by Gregori and colleagues: 
approximate ETDRS = 85 + 50 x log (Snellen fraction).18 All approximate ETDRS scores 
were rounded to the nearest integer. Snellen fractions were converted to LogMAR 
scores using the following formula: -1 x log (Snellen fraction).18 These formulae were 
rearranged to convert between LogMAR and ETDRS. Where a person could only 
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detect light, detect movement or count fingers, a LogMAR score of 2.3, equivalent to 
counting figures, was applied.18 
 
Subgroups 
Results are presented for four subgroups based on higher and lower visual acuity at 
implant (<0.7 and ≥0.7 on LogMAR scale, equivalent to an approximate ETDRS letter 
score of <50 and ≥5018) and number of treatments for DMO prior to implant 
(categorised as six or fewer treatments and more than six treatments). Treatments 
for DMO were defined as laser therapy, steroid treatment (triamcinolone and 
dexamethasone) and anti-vascular endothelial growth factor (anti-VEGF) injection 
(ranibizumab, aflibercept and bevacizumab). People with no baseline visual acuity 
score and no history of receiving any anti-VEGF, macular laser or steroid therapy 
prior to index date were excluded from the subgroup analyses. 
 
Statistical analysis 
Changes in visual acuity (LogMAR scale) and IOP were compared between implant 
and the 3, 6 and 12 month time points using the non-parametric Wilcoxon signed 
ranks test because the variables were not normally distributed. The proportions of 
people achieving an improvement in visual acuity between implant and the 3, 6 and 
12 month time points were compared between subgroups using Fisher’s exact test. 
Mean and median visual acuity (LogMAR scale) were calculated on a daily basis for 
the 12 months prior to and post FAc implant. In order to smooth the data, missing 
values for each day of this 24 month period were imputed using linear 
interpolation.19 As linear interpolation could not be used before the first recorded 
value or after the last recorded value, nearest observation carried forward and 
backwards were used to impute the remaining missing values. Last observation 
carried forward was implemented to impute missing values in all other analyses 
where change in study outcomes were evaluated at 3, 6 and 12 month follow-up 
time points.19 Missing values were imputed in two stages: ≤index date and >index 
date. Statistical analyses were carried out using IBM SPSS statistics version 20.  
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Results 
Data were collected on 311 people, of which 208 people contributing 233 eyes 
treated with FAc intravitreal implant were eligible for inclusion in the study cohort 
(Figure 1). 205 people (99%) had bilateral DMO at implant. Of the 233 eyes treated, 
208 were first eyes treated with the implant and 25 were a second eye in the same 
person.  
 
Patient characteristics 
Of the 208 people treated in any eye, 128 (62%) were male. Mean age was 68.1 
years. 176 (85%) had type 2 diabetes (Table 1). Median (IQR) duration of diabetes 
was 18 (11–28) years. 
216 treated eyes had a baseline visual acuity score and a history of receiving at least 
one treatment for DMO (steroid, macular laser or anti-VEGF therapies). Of these, 89 
eyes (41%) had previously received six or fewer prior treatments. Visual acuity was 
<0.7 LogMAR units in 45 eyes (21%) and ≥0.7 LogMAR units in 44 eyes (20%). 127 
eyes (59%) had received more than six prior anti-VEGF, macular laser or steroid 
therapies prior to implant. Here, visual acuity was <0.7 LogMAR units in 63 (29%) 
eyes and ≥0.7 LogMAR units in 64 eyes (30%).  
207 treated eyes (89%) had a pseudophakic lens at the time of implant. Median (IQR) 
visual acuity at implant was 0.66 (0.48–1.00) LogMAR units. Mean (SD) central foveal 
thickness at implant was 482 m (186 m), and median (IQR) IOP was 15.0 (13.0–
18.0) mmHg. Median (IQR) number of macular laser treatments, steroid treatments 
and anti-VEGF injections prior to index date was 1.0 (0.0–3.0), 0.0 (0.0–1.0) and 5.0 
(2.0–7.0), respectively. Baseline characteristics by visual acuity and treatment 
subgroups are described in Table 1 and Supplementary Table 1. 
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Intraocular therapies  
At FAc implant, 191 eyes (82%) had received at least one prior anti-VEGF treatment 
(Table 2). 13 (6%), 21 (9%) and 41 (18%) treated eyes received additional anti-VEGF 
treatment between 0 and 3 months, 3 and 6 months and 6 and 12 months post FAc 
implant. 3 (1%), 3 (1%) and 11(5%) treated eyes received additional steroid therapy 
between 0 to 3 months post index date, 3 to 6 months post index date and 6 to 12 
months post index date, respectively. The corresponding figures for laser therapy 
were 4 (2%), 6 (3%) and 11 (5%) procedures, respectively. Over the 12 month follow-
up period, additional treatments for DMO were used in 69 (30%) of treated eyes. 
Cataract operations were conducted in 19 eyes between 0 to 3 months. However, 14 
of these operations were conducted on the same date as the eye was implanted. A 
cataract operation was conducted on one treated eye between 3 and 12 months 
post implant.  
 
Visual acuity 
In the 12 month period prior to FAc implant, a decrease in visual acuity was observed 
(median 0.6 to 0.66 LogMAR units [55.0 to 52.0 ETDRS letters], mean 0.72 to 0.76 
LogMAR units [50 to 47.5 ETDRS letters] from 12 months prior to index date, Figure 
2). Following implant, visual acuity improved (median 0.55 and 0.60 LogMAR units 
[57.5 and 55.0 ETDRS letters] and mean 0.65 and 0.67 LogMAR units [52.9 and 51.8 
ETDRS letters] on months 4 and 12 post implant).  
Median (IQR) visual acuity in treated eyes changed from 0.64 (0.48–1.00) to 0.54 
(0.40–0.90) LogMAR units between implant and 3 months (p<0.001), from 0.66 
(0.50–1.0) to 0.54 (0.32–0.82) LogMAR units between implant and 6 months 
(p<0.001) and from 0.66 (0.50–1.00) to 0.60 (0.40–0.86) LogMAR units between 
implant and 12 months (p<0.001, Table 3). Following conversion to ETDRS letter 
score, median (IQR) visual acuity changed from 53.0 (35.0–61.0) to 58.0 (40.0–65.0) 
letters between implant and 3 months, from 52.0 (35.0–61.0) to 58.0 (41.5–69.0) 
letters between implant and 6 months and from 52.0 (35.0–61.0) to 55.0 (40.0–66.0) 
letters between implant and 12 months. 
 10 
Change in visual acuity score by subgroup is detailed in Figure 4 and Supplementary 
Figure 3. A significant improvement in visual acuity was observed at all time points in 
those eyes with a visual acuity score of ≥0.7 LogMAR units at implant, regardless of 
treatment subgroup (six or fewer and more than six anti-VEGF, steroid and macular 
laser therapies prior to index date; Table 3). At 12 months post FAc implant, a non-
significant improvement in visual acuity was observed in those with a visual acuity 
score of <0.7 LogMAR units at baseline (median [IQR] 0.48 [0.3–0.54] LogMAR units 
or 65 [55–75 ETDRS] letters at implant and 0.4 [0.2–0.6] LogMAR units or 64.5 [55–
74.5] letters at 12 months post implant, p=0.390). Similarly, a non-significant 
improvement in visual acuity was observed in the same eyes when analysed by 
treatment subgroup. 
When analysed using ETDRS score, visual acuity improved by at least five letters in 
91 (45%), 107 (49%) and 99 (44%) of the treated eyes at 3 months, 6 months and 12 
months post implant, respectively (Figure 3). The corresponding visual acuity scores 
for an improvement of ≥10 letters were 56 (28%), 73 (33%) and 68 (30%), 
respectively. 30 (15%), 38 (17%) and 41 (18%) eyes had an improvement in ETDRS 
score of at least 15 letters at 3 months, 6 months and 12 months post index, 
respectively. The corresponding figures by visual acuity and treatment subgroup are 
detailed in Figure 3 and Supplementary Figure 2. No significant association between 
the number of prior treatments (six or fewer and more than six) and the 
achievement of an improvement of ≥5 letters, ≥10 letters and ≥15 letters in ETDRS 
score from implant to the three time points was observed within each visual acuity 
subgroup (<0.7 and ≥0.7 LogMAR units). In those eyes with a pseudophakic lens at 
implant, 36 (17%) had an improvement in ETDRS letter score of ≥15 letters at 12 
months. Visual acuity worsened by ≥5 letters in 53 (24%) eyes, ≥10 letters in 31 
(14%) eyes and ≥15 letters in 20 (9%) eyes between FAc implant and 12 months 
follow-up. 
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Intraocular pressure 
Median (IQR) IOP increased from implant to each time point: 15.0 (13.0–18.0) mmHg 
at implant to 17.0 (14.0–20.0) mmHg at 3 months (p<0.001), 15.0 (13.0–18.0) mmHg 
at implant to 17.0 (15.0–20.0) mmHg at 6 months (p<0.001) and 15.0 (13.0–18.0) 
mmHg at implant to 18.0 (15.0–21.0) mmHg at 12 months (p<0.001; Table 4).  
5 (3%), 15 (8%) and 29 (15%) people with no history of receiving IOP-lowering 
therapies prior to FAc intravitreal implant were prescribed IOP-lowering therapy 
between 0 to 3 months, 0 to 6 months and 0 to 12 months post implant (Table 5). 
IOP was <21 mmHg in 141 (90%) treated eyes at FAc implant and 127 (81%) treated 
eyes at 3 months (p=0.029). 159 (91%) and 137 (78%) treated eyes had an IOP of <21 
mmHg at FAc implant and 6 months, respectively (p=0.002). The corresponding 
values at implant and 12 months were 165 (91%) and 135 (75%), respectively 
(p<0.001). 
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Discussion 
In the 12 months prior to the FAc implant, a decline in visual acuity was observed. 
Following FAc intravitreal implant, there was an overall improvement in visual acuity 
at 3, 6 and 12 months. Visual acuity improved by at least 15 letters in nearly one fifth 
of treated eyes at 12 months post implant. After insertion of FAc intravitreal implant, 
there was a small but statistically significant increase in median IOP recorded at 3, 6 
and 12 months, but this remained below a median value of 21 mmHg at each time 
point. 15% of subjects were newly treated with IOP-lowering medication in the first 
12 month period following FAc implant. Additional concomitant treatments for DMO 
were used in 30% of treated eyes during the 12 month study follow-up period. This 
needs to be taken into account when interpreting these results. 
In the UK, NICE recommends the use of FAc only in DMO-affected eyes that have an 
artificial lens and are insufficiently responsive to other treatments.20 90% of treated 
eyes in the ICE-UK study cohort were pseudophakic, with a further 6% receiving a 
cataract operation on the same day as the FAc implant. 97% of eyes had previously 
been treated with at least one anti-VEGF, steroid or laser therapy prior to index.  
In the FAME trial—randomised with a sham injection—it was found that 29% of eyes 
treated with 0.2 µg/day FAc intravitreal implant achieved a 15-letter improvement in 
visual acuity at 24 months following implant insertion versus 16% (p=0.002) in the 
sham treated group.3 Of those patients randomised to 0.2 µg/day FAc implant, 23% 
demonstrated ≥15 letter improvement in visual acuity over baseline at 12 months.3 
At 12 months post implant, we similarly found that 18% of treated eyes achieved an 
improvement in visual acuity of ≥15 letters. The FAMOUS (Fluocinolone Acetonide in 
Human Aqueous) trial randomly allocated individuals with DMO previously treated 
with a least one laser therapy to receive high or low dose FAc intravitreal implant 
and reported that 15% of people receiving the 0.2 µg/day implant achieved a 15 
letter improvement in visual acuity at 12 months post implant.21  
Compared with FAME, there was a higher percentage of people with type 1 diabetes 
in the ICE study cohort.3 In addition, the people included in the ICE study were 
generally older, with a higher proportion of treated eyes with a pseudophakic lens.3 
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Visual acuity at implant was lower in this study (median LogMAR 0.66 units, 
converting to an ETDRS score of 47 letters compared with a mean of 53.4 letters in 
the FAME study).3 Cunha-Vaz and colleagues reported that the percentage of people 
in the FAME trial that gained a 15 letter improvement in visual acuity following 
implant was significantly higher in those with chronic DMO versus those with non-
chronic DMO.22 Unfortunately, chronicity of DMO was not recorded in the ICE-UK 
study. However, the highest percentage of people achieving a ≥15 letter 
improvement in ETDRS score at 12 months was observed in those with poorer vision 
at implant (≥0.7 LogMAR units) and a history of receiving a greater number of anti-
VEGF, steroid or laser treatments (more than six). In a retrospective study by 
Elaraoud and colleagues, an improvement in visual acuity and central retinal 
thickness was observed in 15 out of 22 pseudophakic eyes treated with FAc 
intravitreal implant, the majority of which had been previously treated with multiple 
anti-VEGF and laser therapies.14 In a recent retrospective study by El-Ghrably and 
colleagues, 5 out of 22 eyes (22.7%) achieved an increase in ETDRS letter score of 
≥15 letters at 12 months.17 As with this study, a small decrease in visual acuity was 
reported between 6 and 12 months post FAc implant.17 
In the FAME study, the most commonly reported adverse event was cataract 
surgery, which was listed as an adverse event in 75% of the low-dose group, 85% of 
the high-dose group, and 23% of the sham group after 24 months of follow-up in 
those with no history of cataract surgery at implant.3 At 36 months, cataracts were 
reported in 82%, 89%, and 50% of the people with no prior history of cataract 
surgery in each of the groups, respectively.2 In this study, 19 cataract operations 
were observed between 0 and 3 months post-implant, where 14 of these operations 
were carried out on the day of implant. However, cataract development is likely to 
have pre-dated FAc implant in these cases and it is probable that these operations 
were carried out on pre-existing conditions. No cataract surgeries were recorded 
between 3 and 12 months post-implant. However, the high proportion of treated 
eyes with a pseudophakic lens at implant needs to be considered when interpreting 
this observation (90% versus 35% in the FAME study).3 
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Steroids are known to be associated with raised intraocular pressure and the FAc 190 
µg intravitreal implant is contraindicated in people with glaucoma. Although the 
number of patients with glaucoma at the time of implant was not known, 19% of 
study eyes had been treated with IOP-lowering therapy prior to insertion of the FAc 
implant in the current study.3 Following FAc implant, a small but statistically 
significant increase in IOP was found at 3, 6 and 12 months. However, the median 
IOP remained below 21 mmHg. 15% of eyes with no history of receiving IOP-lowering 
therapy prior to FAc intravitreal implant were prescribed IOP-lowering therapy 
between 0 and 12 months post implant. IOP-lowering surgery was required in only 
one eye between 3 and 6 months post implant and in one eye at 6 to 12 months post 
index. The first eye (treated between 3 and 6 months post implant) had a history of 
IOP-lowering therapy prior to implant. The second eye had no history of glaucoma 
prior to implant. In the FAME trials, people with glaucoma were excluded. A higher 
proportion of treated eyes required glaucoma surgery in the FAME study, where 
laser trabeculoplasty and incisional IOP-lowering surgery were carried out in 1.3% 
and 4.8% of eyes treated with the 0.2 µg/day FAc implant and 0% and 0.5% of those 
treated with sham, respectively.2 However, IOP increases were manageable and did 
not affect vision outcomes.23 In the FAME trials, FAc was not associated with 
significant glaucomatous changes in the optic nerve head in those with or without 
raised IOP.24  
 
Strengths and limitations 
Several measures were taken to maintain consistency in data entry. All data-entry 
personnel received one-to-one training and continued support. Eligibility criteria 
were checked both prior to data entry and after any new record had been entered. 
The online database included partial validation upon data entry, and the user 
interface and data entry processes were designed to minimise errors and achieve 
consistency between centres. New data entered were checked daily for irregularities 
and data entry progress was monitored and logged.  
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As this is an observational study, several limitations may occur. Retrospective studies 
are subject to bias and confounding and can only be used to infer association and 
not causation. Medical records may be incomplete for patients who switch 
ophthalmology centres. Recording of procedures occurring near the end of the study 
observation period (15 April 2016) may also be incomplete. Misclassification of 
outcomes, effectiveness and safety may have occurred, although data were taken 
from patient notes and electronic medical records. As data were collected from 
routine secondary care, outcomes were not measured at set times post index. 
Individual information on exposures and outcome was not consistently available 
across all participating centres for all the time points planned in the analysis. Last 
observation carried forward minimised the elimination of individuals from the 
analysis but can produce a biased estimate of treatment effect and smaller standard 
errors. However, as visual acuity continued to improve over the follow-up period, we 
believe that the use of last observation carried forward will provide a conservative 
estimate of the effectiveness of FAc. However, for IOP, which continued to worsen 
over the period of follow-up, the results may be optimistic. Recall of participants for 
review may have led to differential misclassification and missing values. Duration of 
diagnosed DMO was not recorded. Unfortunately, information recorded for lens 
status and cataract status was inconsistent in some people, potentially leading to 
misclassification. Data on lens status and cataract operations for each eye were 
scrutinised in order to classify phakic and pseudophakic lens status at implant and 
the presence of cataract operations post implant. However, some eyes were 
classified as having a pseudophakic lens at index date but had no history of receiving 
a cataract operation. Visual acuity scores recorded on the same date as the first 
administration of FAc intravitreal implant were assumed to have been measured 
prior to implant. Analysis was restricted to 12 months follow-up post implant 
because available follow-up after this date varied from person to person. 
First and second treated eyes from the same individual were analysed as 
independent observations. However, FAc implant in a second eye may be more likely 
if the first eye responded positively to FAc implant. In addition, bilateral treatment 
with FAc implant may be more likely to occur at certain treatment centres. 
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The date on which age and duration of diabetes was recorded was not documented. 
Therefore, it was not possible to determine the subject’s exact age or their duration 
of diabetes at implant. The dataset included other parameters where a specific event 
date was not recorded (lens status, visual acuity score, central foveal thickness and 
IOP). In these cases, the date of the event was defined as the review date. Due to the 
retrospective nature of the ICE-UK study, it was not possible to ensure that visual 
acuity was recorded using the same standardised method. Visual acuity was 
recorded as one of: Snellen fractions, ETDRS letter score or LogMAR units. 
Conversion was required for data analysis, and the method adopted by Gregori and 
colleagues was used.18 However, the use of a standardised method for measuring 
visual acuity using ETDRS letter score is likely to have provided more accurate visual 
acuity measurements. People who could only count fingers or detect movement or 
light at implant were attributed a LogMAR score of 2.3, the LogMAR score applied to 
people who can count fingers. Therefore, visual acuity on the LogMAR scale was 
overestimated in those people that could only detect movement or light.  
Conclusion 
In the 12 months prior to FAc implantation, a decline in visual acuity was observed. 
Following FAc implantation, an overall improvement in visual acuity was observed 
over a period of 12 months. A small but significant increase in IOP was observed 
following FAc implant, which required emergent IOP-lowering therapy in 15% of FAc-
treated eyes.  
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Tables and figures 
Supplementary Figure 1 | Flow diagram illustrating patient data capture for first treated ILUVIEN eye for the cohort of patients 
included in ICE-UK 
 
Anti-VEGF = anti-vascular endothelial growth factor, FAc = fluocinolone acetonide.
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Figure 1 | Attrition 
 
FAc = fluocinolone acetonide, VEGF = vascular endothelial growth factor
 23 
Table 1 | Baseline characteristics overall and by visual acuity and treatment subgroup 
Parameter All study eyes VA <0.7 LogMAR units at FAc implant VA ≥0.7 LogMAR units at FAc implant 
≤6 prior treatments 
for DMO 
>6 prior treatments 
for DMO 
≤6 prior treatments 
for DMO 
>6 prior treatments 
for DMO 
Subjects, n 208 
 
44 
 
55 
 
43 
 
60 
 
First eyes treated, n (%)a 208 (89%) 43 (96%) 51 (81%) 41 (93%) 58 (91%) 
Second eyes treated, n (%)b 25 (11%) 2 (4%) 12 (19%) 3 (7%) 6 (9%) 
All treated eyes, n (%) 233 
 
45 (19%) 63 (27%) 44 (19%) 64 (27%) 
   
0.21 
 
0.29 
 
0.20 
 
0.30 
 
Patient characteristics 
          
Age last clinic visit, mean (SD), yearsc 68.1 (10.7) 69 (11.5) 67.6 (10.9) 69 (10.1) 68.1 (10.1) 
Males, n (%) 128 (62%) 30 (68%) 39 (71%) 23 (53%) 36 (60%) 
Type 2 diabetes, n (%) 176 (85%) 36 (82%) 43 (78%) 39 (91%) 55 (92%) 
Oral antihyperglycaemic agents 76 (43%) 17 (47%) 17 (40%) 19 (49%) 23 (42%) 
Insulin 43 (24%) 11 (31%) 10 (23%) 9 (23%) 12 (22%) 
Insulin plus oral antihyperglycaemic agents 57 (32%) 8 (22%) 16 (37%) 11 (28%) 20 (36%) 
Type 1 diabetes, n (%) 32 (15%) 8 (18%) 12 (22%) 4 (9%) 5 (8%) 
Oral antihyperglycaemic agents 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Insulin 28 (88%) 6 (75%) 11 (92%) 3 (75%) 5 (100%) 
Insulin plus oral antihyperglycaemic agents 4 (13%) 2 (25%) 1 (8%) 1 (25%) 0 (0%) 
Duration of diabetes, median (IQR), yearsc 18 (11–27) 14.5 (10–25) 20 (14.5–30.5) 15 (10.5–25) 20.5 (14–28) 
           
Treated eye characteristics 
          
Duration of treated DMO, median (IQR), years 2.7 (1.1–4.8) 1.0 (0.7–2.7) 4.1 (2.3–6) 2.3 (1.1–3.9) 3.2 (2.3–5.6) 
Pseudophakic lens status, n (%)d 207 (89%) 38 (84%) 56 (89%) 40 (91%) 57 (89%) 
Visual acuity, LogMAR units 
          
n (%) 224 (96%) 45 (100%) 63 (100%) 44 (100%) 64 (100%) 
Median (IQR) 0.66 (0.48–1) 0.42 (0.3–0.5) 0.5 (0.34–0.54) 1 (0.89–1.53) 1 (0.8–1.1) 
Central subfield thickness, µm 
          
n (%) 198 (85%) 41 (91%) 54 (86%) 38 (86%) 59 (92%) 
Median (IQR) 447 (352–587) 433 (330–523) 424 (324–492) 500 (378–652) 511 (371–632) 
Central foveal thickness, µm 
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n (%) 191 (82%) 42 (93%) 52 (83%) 37 (84%) 54 (84%) 
mean (SD) 482 (186) 449.9 (171.4) 422 (154.8) 530 (206.3) 544.3 (192.2) 
IOP, mmHg 
          
n (%) 185 (79%) 40 (89%) 53 (84%) 35 (80%) 48 (75%) 
Median (IQR), mmHg 15 (13–18) 15 (13–17) 15 (12–18) 14 (12–18) 17 (14–18) 
Prior macular laser treatments 
          
n (%) 146 (63%) 17 (38%) 48 (76%) 31 (70%) 47 (73%) 
Median (IQR) 1 (0–3) 0 (0–1) 2 (1–5) 1 (0–2) 1.5 (0–3) 
Time since first laser, median (IQR), years 3.8 (2.1–6.1) 3.3 (1.1–5.5) 4.2 (3.1–6.8) 3.0 (1.8–5.5) 4.1 (2–6.1) 
Time since last laser, median (IQR), years 2.2 (1.2–3.9) 1.9 (1–3.6) 2.7 (2–4.2) 1.9 (0.7–3) 2.0 (1–3.4) 
Prior anti–VEGF injections 
          
n (%) 191 (82%) 37 (82%) 62 (98%) 27 (61%) 58 (91%) 
Median (IQR) 5 (2–7) 3 (1–4) 7 (5–10) 1 (0–3) 7 (5.5–9.5) 
Time since first injection, median (IQR), years 1.2 (0.8–2.5) 0.7 (0.6–1) 1.3 (1–2.7) 0.7 (0.5–1.1) 1.8 (1.2–2.9) 
Time since last injection, median (IQR), years 0.4 (0.2–0.7) 0.3 (0.2–0.6) 0.4 (0.2–0.7) 0.4 (0.3–0.6) 0.4 (0.3–0.6) 
Prior ranibizumab injections 
          
n (%) 162 (70%) 31 (69%) 56 (89%) 22 (50%) 52 (81%) 
Median (IQR) 3 (0–6) 2 (0–4) 6 (3–8) 0.5 (0–3) 6 (2–7) 
Prior aflibercept injections 
          
n (%) 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior bevacizumab injections 
          
n (%) 74 (32%) 6 (13%) 23 (37%) 6 (14%) 33 (52%) 
Median (IQR) 0 (0–2) 0 (0–0) 0 (0–3) 0 (0–0) 1 (0–4) 
Prior steroid injections, 
          
n (%) 101 (43%) 9 
 
30 
 
16 
 
43 
 
Median (IQR) 0 (0–1) 0 (0–0) 0 (0–1) 0 (0–1) 1 (0–2) 
Time since first injection, median (IQR), years 2.2 (1.1–2.9) 2.1 (1.1–2.7) 2.0 (0.9–2.7) 1.6 (0.6–2.6) 2.4 (2–3.9) 
Time since last injection, median (IQR), years 1.8 (0.7–2.7) 2.1 (1.1–2.7) 1.2 (0.5–2.5) 1.1 (0.4–1.8) 2.3 (1.5–3.3) 
Prior dexamethasone injections 
          
n (%) 17 (7%) 0 (0%) 6 (10%) 3 (7%) 8 (13%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior triamcinolone injections 
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n (%) 88 (38%) 9 (20%) 25 (40%) 13 (30%) 38 (59%) 
Median (IQR) 0 (0–1) 0 (0–0) 0 (0–1) 0 (0–1) 1 (0–1) 
IOP-lowering medication, n (%) 44 (19%) 8 (18%) 6 (10%) 9 (20%) 14 (22%) 
Prostaglandin analogues, n (%) 26 (11%) 5 (11%) 4 (6%) 6 (14%) 9 (14%) 
Beta blockers, n (%) 17 (7%) 1 (2%) 2 (3%) 5 (11%) 6 (9%) 
Alpha agonists, n (%) 5 (2%) 1 (2%) 1 (2%) 0 (0%) 3 (5%) 
Carbonic anhydrase inhibitors, n (%) 11 (5%) 2 (4%) 0 (0%) 1 (2%) 5 (8%) 
Other, n (%) 8 (3%) 3 (7%) 1 (2%) 2 (5%) 1 (2%) 
FAc = fluocinolone acetonide, VA = visual acuity, DMO = diabetic macular oedema, SD = standard deviation, IQR = interquartile range, IOP = intraocular pressure, VEGF = 
vascular endothelial growth factor, IQR = interquartile range, LogMAR = logarithm of the minimum angle of resolution, ETDRS = Early treatment diabetic retinopathy study. 
a These are approximate estimates as it was not possible to determine the exact date on which these parameters were recorded in the dataset. 
Although some of the characteristics relate to the individual and not the eye, each eye was analysed as an independent observation. 
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Supplementary Table 1 | Baseline characteristics by visual acuity or treatment subgroup 
 
Parameter 
VA <0.7 LogMAR units 
at FAc implant 
VA ≥0.7 LogMAR units 
at FAc implant 
≤6 prior treatments for 
DMO 
>6 prior treatments for 
DMO 
Subjects, n 99 
 
103 
 
8785 
 
11111 
 
First eyes treated, n (%)a 94 (87%) 99 (92%) 84 (94%) 109 (86%) 
Second eyes treated, n (%)b 14 (13%) 9 (8%) 5 (6%) 18 (14%) 
All treated eyes, n (%) 108 (46%) 108 (46%) 89 (38%) 127 (55%) 
 
       
 
Patient characteristics 
        
Age last clinic visit, mean (SD), yearsc 68.2 (11.2) 68.3 (10) 69.1 (10.8) 67.8 (10.2) 
Males, n (%) 68 (69%) 58 (57%) 51 (60%) 73 (66%) 
Type 2 diabetes, n (%) 79 (81%) 93 (91%) 73 (86%) 95 (86%) 
Oral antihyperglycaemic agents 34 (43%) 42 (45%) 34 (47%) 38 (40%) 
Insulin 21 (27%) 20 (22%) 20 (27%) 22 (23%) 
Insulin plus oral antihyperglycaemic agents 24 (30%) 31 (33%) 19 (26%) 35 (37%) 
Type 1 diabetes, n (%) 19 (19%) 9 (9%) 12 (14%) 16 (14%) 
Oral hypoglycaemic agents 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Insulin 16 (84%) 8 (89%) 9 (75%) 15 (94%) 
Insulin plus oral antihyperglycaemic agents 3 (16%) 1 (11%) 3 (25%) 1 (6%) 
Duration of diabetes, median (IQR), yearsc 18 (11–27.5) 19 (11.5–26.5) 15 (10–25) 20 (13.8–28) 
         
Treated eye characteristics 
        
Duration of treated DMO, median (IQR), years 2.7 (1–4.8) 2.8 (1.8–5.1) 1.4 (0.8–3.3) 3.8 (2.3–5.8) 
Pseudokaphic lens status, n (%)d 94 (87%) 97 (90%) 78 (88%) 113 (89%) 
Visual acuity, LogMAR units 
        
n (%) 108 (100%) 108 (100%) 89 (100%) 127 (100%) 
Median (IQR) 0.48 (0.3–0.52) 1 (0.8–1.3) 0.66 (0.42–1) 0.7 (0.5–1) 
Central subfield thickness, µm 
        
n (%) 95 (88%) 97 (90%) 79 (89%) 113 (89%) 
Median (IQR) 429 (327–514) 510 (374–634) 450 (361–600) 453 (359–587) 
Central foveal thickness, µm 
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n (%) 94 (87%) 91 (84%) 79 (89%) 106 (83%) 
mean (SD) 434.4 (162.1) 538.5 (197) 487.4 (191.6) 484.3 (184.6) 
IOP, mmHg 
        
n (%) 93 (86%) 83 (77%) 75 (84%) 101 (80%) 
Median (IQR), mmHg 15 (13–17) 15 (13–18) 15 (13–17) 15 (13–18) 
Prior macular laser treatments 
        
n (%) 65 (60%) 78 (72%) 48 (54%) 95 (75%) 
Median (IQR) 1 (0–2.5) 1 (0–3) 1 (0–2) 2 (0–4) 
Time since first laser, median (IQR), years 4.1 (2.6–6.2) 3.1 (2–6.1) 3.0 (1.6–5.5) 4.2 (2.4–6.8) 
Time since last laser, median (IQR), years date 2.6 (1.6–4.2) 2.0 (1–3.2) 1.9 (0.8–3.1) 2.3 (1.5–4.1) 
Prior anti–VEGF injections 
        
n (%) 99 (92%) 85 (79%) 64 (72%) 120 (94%) 
Median (IQR) 5 (3–7) 5 (1–8) 2 (0–4) 7 (5–10) 
Time since first injection, median (IQR), years 1.1 (0.7–1.8) 1.3 (0.8–2.6) 0.7 (0.5–1) 1.5 (1–2.8) 
Time since last injection, median (IQR), years 0.4 (0.2–0.6) 0.4 (0.3–0.6) 0.3 (0.2–0.6) 0.4 (0.2–0.7) 
Prior ranibizumab injections 
        
n (%) 87 (81%) 74 (69%) 53 (60%) 108 (85%) 
Median (IQR) 4 (1.5–6) 3 (0–6) 1 (0–3) 6 (2–7) 
Prior aflibercept injections 
        
n (%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior bevacizumab injections 
        
n (%) 29 (27%) 39 (36%) 12 (13%) 56 (44%) 
Median (IQR) 0 (0–1) 0 (0–3) 0 (0–0) 0 (0–3) 
Prior steroid injections, 
        
n (%) 39 
 
59 
 
25 
 
73 
 
Median (IQR) 0 (0–1) 1 (0–1) 0 (0–1) 1 (0–2) 
Time since first injection, median (IQR), years 2.1 (0.9–2.7) 2.3 (1.3–3.3) 1.8 (0.7–2.7) 2.3 (1.1–3.3) 
Time since last injection, median (IQR), years 1.4 (0.5–2.7) 2.2 (0.9–3.2) 1.3 (0.5–2.4) 2.1 (0.8–2.8) 
Prior dexamethasone injections 
        
n (%) 6 (6%) 11 (10%) 3 (3%) 14 (11%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior triamcinolone injections 
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n (%) 34 (31%) 51 (47%) 22 (25%) 63 (50%) 
Median (IQR) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–1) 
IOP–lowering medication, n (%) 14 (13%) 23 (21%) 17 (19%) 20 (16%) 
Prostaglandin analogues, n(%) 9 (8%) 15 (14%) 11 (12%) 13 (10%) 
Beta blockers, n (%) 3 (3%) 11 (10%) 6 (7%) 8 (6%) 
Alpha agonists, n (%) 2 (2%) 3 (3%) 1 (1%) 4 (3%) 
Carbonic anhydrase inhibitors, n (%) 2 (2%) 6 (6%) 3 (3%) 5 (4%) 
Other, n (%) 4 (4%) 3 (3%) 5 (6%) 2 (2%) 
FAc = fluocinolone acetonide, VA = visual acuity, DMO = diabetic macular oedema, SD = standard deviation, IQR = interquartile range, IOP = intraocular pressure, VEGF = 
vascular endothelial growth factor, IQR = interquartile range, LogMAR = logarithm of the minimum angle of resolution, ETDRS = Early treatment diabetic retinopathy study. 
a These are approximate estimates as it was not possible to determine the exact date on which these parameters were recorded in the dataset. 
Although some of the characteristics relate to the individual and not the eye, each eye was analysed as an independent observation.
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Table 2 | Number of eyes prescribed other interventions before and after treatment with fluocinolone intravitreal implant  
 
Prior to implant 0 to 3 months 3 to 6 months 6 to 12 months 
Anti-VEGF injections 
        
Overall 191 (82%) 13 (6%) 21 (9%) 41 (18%) 
Visual acuity subgroup 
        
<0.7 LogMAR units 99 (92%) 8 (7%) 12 (11%) 23 (21%) 
≥0.7 LogMAR units 85 (79%) 2 (2%) 7 (6%) 16 (15%) 
Treatment subgroup 
        
≤6 treatments 64 (72%) 2 (2%) 7 (8%) 17 (19%) 
>6 treatments 120 (94%) 8 (6%) 12 (9%) 22 (17%) 
Visual acuity and treatment subgroups 
combined 
        
<0.7 LogMAR units and ≤6 treatments 37 (82%) 1 (2%) 6 (13%) 12 (27%) 
<0.7 LogMAR units and >6 treatments 62 (98%) 7 (11%) 6 (10%) 11 (17%) 
≥0.7 LogMAR units and ≤6 treatments 27 (61%) 1 (2%) 1 (2%) 5 (11%) 
≥0.7 LogMAR units and >6 treatments 58 (91%) 1 (2%) 6 (9%) 11 (17%) 
Steroid injections (excluding FAc implant) 
        
Overall 101 (43%) 3 (1%) 3 (1%) 11 (5%) 
Visual acuity subgroup 
        
<0.7 LogMAR units 39 (36%) 1 (1%) 1 (1%) 2 (2%) 
≥0.7 LogMAR units 59 (55%) 2 (2%) 2 (2%) 7 (6%) 
Treatment subgroup 
        
≤6 treatments 25 (28%) 0 (0%) 1 (1%) 4 (4%) 
>6 treatments 73 (57%) 3 (2%) 2 (2%) 5 (4%) 
Visual acuity and treatment subgroups 
combined 
        
<0.7 LogMAR units and ≤6 treatments 9 (20%) 0 (0%) 0 (0%) 1 (2%) 
<0.7 LogMAR units and >6 treatments 30 (48%) 1 (2%) 1 (2%) 1 (2%) 
≥0.7 LogMAR units and ≤6 treatments 16 (36%) 0 (0%) 1 (2%) 3 (7%) 
≥0.7 LogMAR units and >6 treatments 43 (67%) 2 (3%) 1 (2%) 4 (6%) 
Macular laser 
        
Overall 146 (63%) 4 (2%) 6 (3%) 11 (5%) 
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Visual acuity subgroup 
        
<0.7 LogMAR units 65 (60%) 1 (1%) 2 (2%) 4 (4%) 
≥0.7 LogMAR units 78 (72%) 3 (3%) 3 (3%) 7 (6%) 
Treatment subgroup 
        
≤6 treatments 48 (54%) 3 (3%) 1 (1%) 4 (4%) 
>6 treatments 95 (75%) 1 (1%) 4 (3%) 7 (6%) 
Visual acuity and treatment subgroups 
combined 
        
<0.7 LogMAR units and ≤6 treatments 17 (38%) 0 (0%) 1 (2%) 2 (4%) 
<0.7 LogMAR units and >6 treatments 48 (76%) 1 (2%) 1 (2%) 2 (3%) 
≥0.7 LogMAR units and ≤6 treatments 31 (70%) 3 (7%) 0 (0%) 2 (5%) 
≥0.7 LogMAR units and >6 treatments 47 (73%) 0 (0%) 3 (5%) 5 (8%) 
Glaucoma surgery 
        
Overall 0 (0%) 0 (0%) 1 (0%) 1 (0%) 
Visual acuity subgroup 
        
<0.7 LogMAR units 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units 0 (0%) 0 (0%) 1 (1%) 0 (0%) 
Treatment subgroup 
        
≤6 treatments 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
>6 treatments 0 (0%) 0 (0%) 1 (1%) 0 (0%) 
Visual acuity and treatment subgroups 
combined 
        
<0.7 LogMAR units and ≤6 treatments 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
<0.7 LogMAR units and >6 treatments 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units and ≤6 treatments 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units and >6 treatments 0 (0%) 0 (0%) 1 (2%) 0 (0%) 
Vitrectomy         
Overall 50 (21%) 1 (0%) 1 (0%) 2 (1%) 
Visual acuity subgroup 
        
<0.7 LogMAR units 29 (27%) 1 (1%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units 17 (16%) 0 (0%) 1 (1%) 2 (2%) 
Treatment subgroup 
        
≤6 treatments 19 (21%) 0 (0%) 1 (1%) 1 (1%) 
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>6 treatments 27 (21%) 1 (1%) 0 (0%) 1 (1%) 
Visual acuity and treatment subgroups 
combined 
        
<0.7 LogMAR units and ≤6 treatments 11 (24%) 0 (0%) 0 (0%) 0 (0%) 
<0.7 LogMAR units and >6 treatments 18 (29%) 1 (2%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units and ≤6 treatments 8 (18%) 0 (0%) 1 (2%) 1 (2%) 
≥0.7 LogMAR units and >6 treatments 9 (14%) 0 (0%) 0 (0%) 1 (2%) 
Incident cataract operationsa    
     
Overall 207 (89%) 19b (73%) 1 (14%) 0 (0%) 
Visual acuity subgroup 
        
<0.7 LogMAR units 94 (87%) 10 (71%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units 97 (90%) 9 (82%) 1 (50%) 0 (0%) 
Treatment subgroup 
        
≤6 treatments 78 (88%) 6 (55%) 0 (0%) 0 (0%) 
>6 treatments 113 (89%) 13 (93%) 1 (100%) 0 (0%) 
Visual acuity and treatment subgroups 
combined 
        
<0.7 LogMAR units and ≤6 treatments 38 (84%) 3 (43%) 0 (0%) 0 (0%) 
<0.7 LogMAR units and >6 treatments 56 (89%) 7 (100%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units and ≤6 treatments 40 (91%) 3 (75%) 0 (0%) 0 (0%) 
≥0.7 LogMAR units and >6 treatments 57 (89%) 6 (86%) 1 (100%) 0 (0%) 
FAc = fluocinolone acetonide 
a Percentage is calculated as number of operations in eyes with a phakic lens 
b 14 cataract operations carried out on day of FAc implant  
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Figure 2 | Change in visual acuity in the 12 months before and after fluocinolone intravitreal implant 
a) LogMAR scale 
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b) ETDRS letters 
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Visual acuity measurements recorded in the 12 months before and after FAc implant were included. Linear interpolation was used to impute missing values between visual 
acuity scores. Nearest observation carried forward and backwards was used to impute missing values prior to the first and after the last recorded measurement. 
Imputation was carried out in two parts, day -365 to day 0 and day 1 to 365.  
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Table 3 | Change in visual acuity (implant value varies according to availability of pairs of visual acuity values at baseline and 
during follow-up) 
 
N At implant, median (IQR) Post index, median (IQR) p-value 
At 3 months post FAc implant 
      
Overall 202 0.64 (0.48–1) 0.54 (0.4–0.9) <0.001 
Visual acuity subgroup 
      
<0.7 LogMAR units 97 0.48 (0.3–0.5) 0.40 (0.3–0.5) 0.008 
≥0.7 LogMAR units 97 1.00 (0.8–1.3) 0.90 (0.6–1.18) <0.001 
Treatment subgroup 
      
≤6 treatments 78 0.65 (0.42–1.04) 0.50 (0.4–1) 0.002 
>6 treatments 116 0.68 (0.5–1) 0.60 (0.31–0.8) <0.001 
Visual acuity and treatment subgroups combined 
      
<0.7 LogMAR units and ≤6 treatments 39 0.42 (0.3–0.5) 0.40 (0.26–0.5) 0.119 
<0.7 LogMAR units and >6 treatments 58 0.50 (0.34–0.5) 0.40 (0.3–0.5) 0.028 
≥0.7 LogMAR units and ≤6 treatments 39 1.04 (0.9–1.56) 1.00 (0.7–1.5) 0.016 
≥0.7 LogMAR units and >6 treatments 58 1.00 (0.8–1.1) 0.80 (0.6–1) 0.005 
At 6 months post FAc implant 
      
Overall 220 0.66 (0.48–1) 0.54 (0.32–0.87) <0.001 
Visual acuity subgroup 
      
<0.7 LogMAR units 106 0.48 (0.3–0.5) 0.40 (0.3–0.5) 0.002 
≥0.7 LogMAR units 106 1.00 (0.8–1.3) 0.82 (0.6–1) <0.001 
Treatment subgroup 
      
≤6 treatments 87 0.66 (0.42–1) 0.50 (0.3–1) <0.001 
>6 treatments 125 0.70 (0.5–1) 0.50 (0.32–0.8) <0.001 
Visual acuity and treatment subgroups combined 
      
<0.7 LogMAR units and ≤6 treatments 44 0.42 (0.3–0.5) 0.40 (0.28–0.5) 0.045 
<0.7 LogMAR units and >6 treatments 62 0.50 (0.34–0.54) 0.40 (0.3–0.5) 0.017 
≥0.7 LogMAR units and ≤6 treatments 43 1.00 (0.9–1.56) 1.00 (0.7–1.12) 0.003 
≥0.7 LogMAR units and >6 treatments 63 1.00 (0.8–1.1) 0.80 (0.6–1) <0.001 
At 12 months post FAc implant 
      
Overall 223 0.66 (0.48–1.00) 0.60 (0.38–0.90) <0.001 
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Visual acuity subgroup 
      
<0.7 LogMAR units 107 0.48 (0.3–0.54) 0.40 (0.2–0.6) 0.390 
≥0.7 LogMAR units 108 1.00 (0.8–1.3) 0.85 (0.62–1) <0.001 
Treatment subgroup 
      
≤6 treatments 89 0.66 (0.42–1) 0.60 (0.4–0.9) 0.030 
>6 treatments 126 0.70 (0.5–1) 0.60 (0.3–0.84) <0.001 
Visual acuity and treatment subgroups combined 
      
<0.7 LogMAR units and ≤6 treatments 45 0.42 (0.3–0.5) 0.40 (0.26–0.56) 0.436 
<0.7 LogMAR units and >6 treatments 62 0.50 (0.34–0.54) 0.43 (0.2–0.6) 0.600 
≥0.7 LogMAR units and ≤6 treatments 44 1.00 (0.89–1.53) 0.93 (0.78–1.36) 0.025 
≥0.7 LogMAR units and >6 treatments 64 1.00 (0.8–1.1) 0.80 (0.55–1) <0.001 
FAc = fluocinolone acetonide, IQR = interquartile range.
 37 
Figure 3 | Percentage of fluocinolone acetonide treated eyes achieving a) ≥5, ≥10 and ≥15 letter improvement in ETDRS score and 
b) ≥5, ≥10 and ≥15 letter worsening in ETDRS score overall and by visual acuity and treatment subgroup 
a) 
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b) 
 
VA = visual acuity. 
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Supplementary Figure 2 | Percentage of fluocinolone acetonide treated eyes achieving a) ≥5, ≥10 and ≥15 letter improvement in 
ETDRS score and b) ≥5, ≥10 and ≥15 letter worsening in ETDRS score by visual acuity or treatment subgroup 
a) 
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b) 
 
VA = visual acuity.
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Table 4 | Change in intraocular pressure for paired values where these were available (baseline value varies according to 
availability of IOP at baseline and the respective time-point) 
 
N Implant IOP, median (IQR), mmHg Implant IOP, median (IQR), mmHg p-value 
At 3 months post FAc implant 
      
Overall 157 15 (13–18) 17 (14–20) <0.001 
Visual acuity subgroup 
      
<0.7 LogMAR units 77 15 (13–18) 17 (15–20) <0.001 
≥0.7 LogMAR units 71 16 (13–18) 16 (14–19) 0.424 
Treatment subgroup 
      
≤6 treatments 59 15 (13–18) 16 (14–20) 0.018 
>6 treatments 89 16 (13.2–18) 17 (15–20) 0.001 
Visual acuity and treatment subgroups 
combined 
      
<0.7 LogMAR units and ≤6 treatments 29 15.4 (14–17) 17 (15–20) 0.003 
<0.7 LogMAR units and >6 treatments 48 15 (12–18) 17.5 (15–20) <0.001 
≥0.7 LogMAR units and ≤6 treatments 30 15 (13–18) 14 (12–19) 0.566 
≥0.7 LogMAR units and >6 treatments 41 17 (14–18.4) 17 (14.5–19) 0.521 
At 6 months post FAc implant 
      
Overall 175 15 (13–18) 17 (15–20) <0.001 
Visual acuity subgroup 
      
<0.7 LogMAR units 88 15 (12.5–18) 17 (15–20) <0.001 
≥0.7 LogMAR units 78 16 (13–18) 17.45 (14–20) 0.032 
Treatment subgroup 
      
≤6 treatments 70 15 (13–17) 17 (14–19) 0.001 
>6 treatments 96 16 (13.6–18) 18 (15.1–20.5) <0.001 
Visual acuity and treatment subgroups 
combined 
      
<0.7 LogMAR units and ≤6 treatments 37 15 (13–17) 18 (15–20) <0.001 
<0.7 LogMAR units and >6 treatments 51 15 (12–18) 17 (15–20) <0.001 
≥0.7 LogMAR units and ≤6 treatments 33 15 (13–18) 15 (13–19) 0.338 
≥0.7 LogMAR units and >6 treatments 45 17 (14–18) 18 (15.2–21) 0.046 
 42 
At 12 months post FAc implant 
      
Overall 181 15 (13–18) 18 (15–21) <0.001 
Visual acuity subgroup 
      
<0.7 LogMAR units 91 15 (12–18) 18 (15–20) <0.001 
≥0.7 LogMAR units 81 15 (13–18) 18 (14–21) 0.001 
Treatment subgroup 81 18 
    
≤6 treatments 73 15 (13–17) 17 (14–19.9) <0.001 
>6 treatments 99 16 (13–18) 19 (15–21) <0.001 
Visual acuity and treatment subgroups 
combined 
99 19 
    
<0.7 LogMAR units and ≤6 treatments 39 15 (13–17) 17 (15–19) 0.002 
<0.7 LogMAR units and >6 treatments 52 15 (12–18) 19 (16–21) <0.001 
≥0.7 LogMAR units and ≤6 treatments 34 14.5 (13–18) 17.5 (13.3–21) 0.020 
≥0.7 LogMAR units and >6 treatments 47 17 (14–18) 18 (15–21) 0.019 
FAc = fluocinolone acetonide, IQR = interquartile range.  
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Table 5 | Intraocular pressure-lowering therapy before and after implant 
 
All eyes treated with 
IOP-lowering 
therapy prior to 
implant, n (%) 
Eyes not treated 
with IOP-lowering 
therapy prior to 
implant, n (%) 
Eyes newly prescribed IOP-lowering therapy post implant, n (%) 
 
0 to 3 months 0 to 6 months 0 to 12 months 
Overall 44 (19%) 189 (81%) 5 (3%) 15 (8%) 29 (15%) 
Visual acuity subgroup 
          
<0.7 LogMAR units 14 (13%) 94 (87%) 2 (2%) 8 (9%) 15 (16%) 
≥0.7 LogMAR units 23 (21%) 85 (79%) 3 (4%) 6 (7%) 12 (14%) 
Treatment subgroup 
          
≤6 treatments 17 (19%) 72 (81%) 2 (3%) 8 (11%) 12 (17%) 
>6 treatments 20 (16%) 107 (84%) 3 (3%) 6 (6%) 15 (14%) 
Visual acuity and treatment subgroups 
combined 
          
<0.7 LogMAR units and ≤6 treatments 8 (18%) 37 (82%) 0 (0%) 5 (14%) 8 (22%) 
<0.7 LogMAR units and >6 treatments 6 (10%) 57 (90%) 2 (4%) 3 (5%) 7 (12%) 
≥0.7 LogMAR units and ≤6 treatments 9 (20%) 35 (80%) 2 (6%) 3 (9%) 4 (11%) 
≥0.7 LogMAR units and >6 treatments 14 (22%) 50 (78%) 1 (2%) 3 (6%) 8 (16%) 
IOP = intraocular pressure.  
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Figure 4 | Change in visual acuity (LogMAR scale) post index by subgroup 
a) At 3 months by visual acuity subgroup b) At 3 months by treatment subgroup c) At 3 months by visual acuity and treatment 
subgroup 
   
d) At 6 months by visual acuity subgroup e) At 6 months by treatment subgroup f) At 6 months by visual acuity and treatment 
subgroup 
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g) At 12 months by visual acuity subgroup h) At 12 months by treatment subgroup i) At 12 months by visual acuity and treatment 
subgroup 
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Supplementary Figure 3 | Change in visual acuity (by ETDRS letter score) post-index by subgroup 
a) At 3 months by visual acuity subgroup b) At 3 months by treatment subgroup c) At 3 months by visual acuity and treatment 
subgroup 
   
d) At 6 months by visual acuity subgroup e) At 6 months by treatment subgroup f) At 6 months by visual acuity and treatment 
subgroup 
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g) At 12 months by visual acuity subgroup h) At 12 months by treatment subgroup i) At 12 months by visual acuity and treatment 
subgroup 
   
 
 
 
